Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Símbolo de cotizaciónASRT
Nombre de la empresaAssertio Holdings Inc
Fecha de salida a bolsaFeb 12, 1997
Director ejecutivoMr. Brendan P. O'Grady
Número de empleados58
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 12
Dirección100 S. Saunders Road
CiudadLAKE FOREST
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal60045
Teléfono12244197106
Sitio Webhttps://www.assertiotx.com/
Símbolo de cotizaciónASRT
Fecha de salida a bolsaFeb 12, 1997
Director ejecutivoMr. Brendan P. O'Grady
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos